Boston Scientific Corp. will buy Baylis Medical Co. for an upfront payment of $1.75 billion to expand its offering of approved technologies for heart patients.
To read the entire story, you must be logged in.
Please log in now or register with us.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
